"We believe gene therapy represents a potentially new and exciting treatment option for patients with severe forms of beta-thalassemia and sickle cell disease," stated Marina Cavazzana, MD, Professor of Medicine at Paris Descartes University and Research Director at the Centre for Clinical Research in Biotherapy, Necker Hospital, Paris France.
http://www.benzinga.com/news/13/12/4119979/bluebird-bio-announces-first-patient-transplanted-in-phase-12-hgb-205-beta-thalas
http://www.benzinga.com/news/13/12/4119979/bluebird-bio-announces-first-patient-transplanted-in-phase-12-hgb-205-beta-thalas
No comments:
Post a Comment